COPENHAGEN, Denmark, Oct. 18, 2010 (GLOBE NEWSWIRE) -- Summary: Genmab provides an update on the potential regulatory pathway for zalutumumab.
- Genmab has received preliminary feedback from selected national European regulatory authorities and FDA on zalutumumab
- Genmab believes a MAA for zalutumumab in second line head and neck cancer could be pursued based on available clinical data
- Additional clinical study data would be required prior to a US regulatory submission
Genmab A/S (Copenhagen:GEN) announced today an update on the potential regulatory pathway for zalutumumab following preliminary, non-binding discussions with a number of selected national European regulatory authorities and the FDA. Based on overall feedback from regulatory authorities in Europe, Genmab believes a Marketing Authorization Application(MAA) for zalutumumab could be pursued based on the data from the Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who failed standard platinum-based therapy, reported earlier this year. Additional clinical study data would, however, be required prior to submitting a regulatory application in the US.
"Our discussions with the regulatory authorities have been very productive and we are encouraged by the overall feedback we have received," said Prof. Jan vande Winkel, Ph.D., Chief Executive Officer of Genmab. "We are advancing our partnership discussions in earnest and feel confident that our potential future development partner would be able to move forward with a European regulatory filing for zalutumumab."
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.
This Stock Exchange Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products,our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-TF(TM); HuMax-Her2(TM); HuMax-Wnt(TM); HuMax-cMet(TM) and UniBody(R) are all trademarks of Genmab A/S. Arzerra(R) is a trademark of GlaxoSmithKline.
Stock Exchange Release no. 40/2010
CONTACT: Genmab Helle Husted, Vice President, Investor Relations +45 33 44 77 30 M: +45 25 27 47 13 email@example.com